MUSTANG BIO, INC. Research and Development Expense
MUSTANG BIO, INC. (MBIO) reported Research and Development Expense of $2.10 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2019-03-18
- MUSTANG BIO, INC. research and development expense for the quarter ending 2017-12-31 was -$1.40M, a 380.00% decline year-over-year.
- MUSTANG BIO, INC. research and development expense for the quarter ending 2017-09-30 was $500.00K, a 0.00% change year-over-year.
- MUSTANG BIO, INC. research and development expense for the quarter ending 2017-06-30 was $500.00K, a 0.00% change year-over-year.
- MUSTANG BIO, INC. research and development expense for the quarter ending 2017-03-31 was $500.00K, a 0.00% change year-over-year.
- MUSTANG BIO, INC. research and development expense for fiscal 2018 was $2.10M, a 2000.00% increase from fiscal 2017.
- MUSTANG BIO, INC. research and development expense for fiscal 2017 was $100.00K, a 95.00% decline from fiscal 2016.
- MUSTANG BIO, INC. research and development expense for fiscal 2016 was $2.00M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 7 month | Research and Development Expense 9 month | Research and Development Expense 10 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2018-12-31 | $2.10M 10-K · filed 2019-03-18 | |||||
| 2017-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | -$900.00K derived: sum of 2 quarters · filed 2018-03-29 | -$400.00K derived: sum of 3 quarters · filed 2018-03-29 | $100.00K 10-K · filed 2018-03-29 | ||
| 2017-09-30 | $500.00K 10-Q · filed 2017-11-14 | $1.00M derived: sum of 2 quarters · filed 2017-11-14 | $1.50M 10-Q · filed 2017-11-14 | $2.00M derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2017-06-30 | $500.00K 10-Q · filed 2017-08-14 | $1.00M 10-Q · filed 2017-08-14 | $1.50M derived: sum of 3 quarters · filed 2017-08-14 | $2.00M derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2017-03-31 | $500.00K 10-Q · filed 2017-05-15 | $1.00M derived: sum of 2 quarters · filed 2017-05-15 | $1.50M derived: sum of 3 quarters · filed 2017-11-14 | $2.00M derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2016-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $1.00M derived: sum of 2 quarters · filed 2017-11-14 | $1.50M derived: sum of 3 quarters · filed 2017-11-14 | $2.00M 10-K · filed 2017-03-31 | ||
| 2016-09-30 | $500.00K 10-Q · filed 2017-11-14 | $1.00M derived: sum of 2 quarters · filed 2017-11-14 | $1.50M 10-Q · filed 2017-11-14 | |||
| 2016-06-30 | $500.00K 10-Q · filed 2017-08-14 | $1.00M 10-Q · filed 2017-08-14 | ||||
| 2016-03-31 | $500.00K 10-Q · filed 2017-05-15 | |||||
| 2015-12-31 | $1.50M 10-K · filed 2017-03-31 | |||||
| 2015-09-30 | $500.00K 10-Q · filed 2016-11-14 | $1.00M 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |